BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Chubb
Deloitte
US Department of Justice
Fish and Richardson
Dow
QuintilesIMS
Boehringer Ingelheim
Cerilliant

Generated: January 22, 2018

DrugPatentWatch Database Preview

Gadoxetate disodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for gadoxetate disodium and what is the scope of gadoxetate disodium freedom to operate?

Gadoxetate disodium
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Gadoxetate disodium has thirty-three patent family members in twenty-four countries.

One supplier is listed for this compound.
Summary for gadoxetate disodium
International Patents:33
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 162
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:gadoxetate disodium at DailyMed
Pharmacology for gadoxetate disodium

US Patents and Regulatory Information for gadoxetate disodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-001 Jul 3, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for gadoxetate disodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,695,739 Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production ➤ Subscribe
5,798,092 Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for gadoxetate disodium

Supplementary Protection Certificates for gadoxetate disodium

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00182 Netherlands ➤ Subscribe PRODUCT: GADOXETINEZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER HET NATRIUMZOUT. FIRST AUTHORIZATION NO/DATE: 1829 AND 18930, 20040326 (SE); NATIONAL AUTHORIZATION NO/DATE: RVG 31393 AND 31394, 20050113
0405704/01 Switzerland ➤ Subscribe FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE
/2005 Austria ➤ Subscribe PRODUCT NAME: GADOXETSAEURE DINATRIUM; NAT. REGISTRATION NO/DATE: 1-25757, 1-25758 20050302; FIRST REGISTRATION: SE 18929, 18930 20040326
0182 Netherlands ➤ Subscribe 300182, 20100627, EXPIRES: 20150626
C/GB05/021 United Kingdom ➤ Subscribe PRODUCT NAME: GADOXETIC ACID, OPTIONALLY IN THE FORM OF A SALT; REGISTERED: SE 18929 20040326; SE 18930 20040326; UK PL 00053/0348 20041110; UK PL 00053/0349 20041110
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cantor Fitzgerald
US Department of Justice
Johnson and Johnson
Federal Trade Commission
Medtronic
Fish and Richardson
Fuji
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot